Interstitial Lung Disease in Connective Tissue Disease: A Common Lesion With Heterogeneous Mechanisms and Treatment Considerations

Tihong Shao1,2†, Xiaodong Shi3†, Shanpeng Yang4, Wei Zhang5, Xiaohu Li6, Jingwei Shu6, Shehabaldin Alqalyoobi7, Amir A. Zeki8, Patrick S. Leung2* and Zongwen Shuai1*

1 Department of Rheumatology and Immunology, The First Affiliated Hospital of Anhui Medical University, Hefei, China, 2 Division of Rheumatology/Allergy and Clinical Immunology, University of California, Davis, Davis, CA, United States, 3 Rheumatology, First Hospital of Jilin University, Changchun, China, 4 Department of Pharmacy, The First Affiliated Hospital of Anhui Medical University, Hefei, China, 5 Department of Pathology, The First Affiliated Hospital (Yi’anshan Hospital) of Wannan Medical College, Wuhu, China, 6 Department of Radiology, The First Affiliated Hospital of Anhui Medical University, Hefei, China, 7 Internal Medicine - Pulmonary, Critical Care, and Sleep Medicine, Brody School of Medicine, Greenville, NC, United States, 8 Lung Center, Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, U.C. Davis School of Medicine, University of California, Davis, CA, United States

Connective tissue disease (CTD) related interstitial lung disease (CTD-ILD) is one of the leading causes of morbidity and mortality of CTD. Clinically, CTD-ILD is highly heterogenous and involves rheumatic immunity and multiple manifestations of respiratory complications affecting the airways, vessels, lung parenchyma, pleura, and respiratory muscles. The major pathological features of CTD are chronic inflammation of blood vessels and connective tissues, which can affect any organ leading to multi-system damage. The human lung is particularly vulnerable to such damage because anatomically it is abundant with collagen and blood vessels. The complex etiology of CTD-ILD includes genetic risks, epigenetic changes, and dysregulated immunity, which interact leading to disease under various ill-defined environmental triggers. CTD-ILD exhibits a broad spectrums of clinical manifestations: from asymptomatic to severe dyspnea; from single-organ respiratory system involvement to multi-organ involvement. The disease course is also featured by remissions and relapses. It can range from stability or slow progression over several years to rapid deterioration. It can also present clinically as highly progressive from the initial onset of disease. Currently, the diagnosis of CTD-ILD is primarily based on distinct pathology subtype(s), imaging, as well as related CTD and autoantibodies profiles. Meticulous comprehensive clinical and laboratory assessment to improve the diagnostic process and management strategies are much needed. In this review, we focus on examining the pathogenesis of CTD-ILD with respect to genetics, environmental factors, and immunological factors. We also discuss the current state of knowledge and elaborate on the clinical characteristics of CTD-ILD, distinct pathohistological subtypes, imaging...
features, and related autoantibodies. Furthermore, we comment on the identification of high-risk patients and address how to stratify patients for precision medicine management approaches.

Keywords: connective tissue disease, interstitial lung disease, genetics, environmental exposure, autoantibodies, signs and symptoms, risk assessment, therapeutics

INTRODUCTION

Connective tissue disease (CTD) is a heterogeneous group of inflammatory disorders that can affect bone, cartilage, tendons, ligaments, muscle, joints, blood vessels, and even specific organs. Many CTDs such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sjögren’s syndrome (SS), polymyositis (PM)/dermatomyositis (DM), systemic sclerosis (SSc), and mixed connective tissue disease (MCTD) are autoimmune mediated. The major pathological features of autoimmune mediated CTD are chronic inflammation of blood vessels and connective tissues, which can affect any organ leading to multi-system damage.

The human lung is particularly vulnerable to such damage because anatomically it is abundant with collagen and blood vessels that are essential for metabolic, endocrine, and immune functions. Various components of the respiratory system including the airways, vessels, parenchyma, pleura, and respiratory muscles may also be involved (1). In such cases, this manifests clinically as pulmonary interstitial diseases, pulmonary vascular diseases, diffuse alveolar hemorrhage, bronchiolitis, pulmonary parenchymal nodules, pleural lesions or effusions, respiratory muscle weakness, and aspiration pneumonia. Understanding the diverse clinical manifestations and high mortality of interstitial lung disease (ILD) in patients with CTD is important and highly relevant to the practice of rheumatology.

The heterogeneity in disease severity, underlying mechanisms, and clinical manifestations of CTD-ILD can be perplexing. Clinical and research-based rheumatologists are faced with several challenges in the diagnosis and management of CTD-ILD: (a) despite extensive effort, the precise mechanisms that drive CTD-ILD remain unclear; (b) it is easy to miss or misdiagnose patients when they present with pulmonary involvement but without clear immunological manifestations; (c) there is no standard protocol for evaluating a given patient’s condition and assessing disease progression, e.g. when we confirm that the patient is deteriorating, there are no effective methods or biomarkers to determine whether the patient’s deterioration is due to the progression of ILD or other reasons, such as infection or drug-induced causes; (d) CTD-ILD is difficult to treat. CTD-ILD has a more favorable prognosis than idiopathic interstitial pneumonia (IIP) because it can be treated with glucocorticoid (GC) and immunosuppressive agents (2, 3). However, the side effects of these medications, treatment dose(s), and clinical course can vary greatly between patients. Further, once the patient progresses to pulmonary fibrosis, the prognosis becomes less optimistic. Owing to the complexity of treatment, tailoring treatment protocols for CTD-ILD requires vigorous effort and a multidisciplinary team approach often including close collaboration with the patient’s pulmonologist (4, 5).

PATHOGENESIS OF CTD-ILD

ILD refers to a group of heterogeneous non-neoplastic diseases belonging to the category of diffuse parenchymal lung diseases (DPLDs) that affect alveolar epithelial cells, pulmonary capillary endothelial cells, basement membrane, perivascular, and lymphoid tissues. CTD-related ILD (CTD-ILD) can be similar to the IIPs [e.g. idiopathic pulmonary fibrosis (IPF)], especially when the lung is the only organ involved, or the lung injury happened in connective tissues prior to the extrapulmonary manifestations. Genetics (6), environment (7, 8), and immunological factors (9, 10) could be involved in the pathogenesis of CTD-ILD (Figure 1). Here, we discuss our current understanding of genetic predisposition, the environment, and immune regulation of CTD-ILD.

Genetics

The application of high throughput genetic analysis has led to the identification of a number of genetic loci that are associated with the risk of developing CTD-ILD and worse prognosis (11–13). We will discuss major findings regarding the effects of genetic susceptibility and its association with the poor prognosis seen in CTD-ILD. Rare pathogenic mutations in telomere maintenance genes and chromosome-protected terminal telomere shortening are related to pulmonary fibrosis. Newton et al. have examined telomere-related variants in patients with ILD (14). Patients with rare telomere-related variants TERT, TERC, PARN, or RTEL1 exhibit various forms of pulmonary fibrosis, ranging from IPF, interstitial pneumonia with autoimmune features (IPAF), to CTD-ILD. Interestingly, there exists statistical correlations in the mean diagnostic age of patients with different gene mutations. TERC mutation carriers were diagnosed at the earliest age (51 years old) and had a higher incidence of hematological comorbidities. The age of diagnosis was highest in PARN, followed by RTEL1, TERT and TERC, and is consistent with the order of average telomere length (14). Studies have reported that shorter leukocyte telomere length is associated with faster decline in lung function and shorter duration of transplant-free survival in patients with IPAF and CTD-ILD (11–13).

The strongest risk factor for the development of IPF has been identified as the gain-of-function of the MUC5B promoter variant rs3570593, which is observed in more than two-thirds of patients with IPF and accounts for 30% to 35% of the risk of developing disease (15–23). Several studies have demonstrated
that MUC5B minor alleles correlate with the deterioration of lung function and survival rate of IPAF and CTD-ILD (11–13). Compared with non-CTD-ILD controls, the frequency of MUC5B minor allele frequency is higher in CTD-ILD, especially the RA-ILD subgroup (24). Notably, Juge et al. examined the effects of MUC5B promoter variant RS35705950 on RA-ILD and showed that the MUC5B promoter variant was associated with RA-ILD, with a characteristic interstitial pneumonia imaging pattern (6). Genetically driven MUC5B overexpression of MUC5B protein can hinder cilia clearance or disrupt normal lung repair mechanisms (25). Collectively, these studies support that MUC5B is involved in the pathogenesis of CTD-ILD and may be a therapeutic target.

Similar to familial IPF patients, data from exome-sequencing revealed the presence of TTR, RTL1, PARN, or SFTPC mutations in RA-ILD patients, indicating the contribution of IFP-linked genes in RA-ILD susceptibility (26). In addition to common genetic features, RA-ILD and IPF patients have overlapping clinical features, such as older age, and higher occurrence in males and in cigarette smokers (27, 28). Cumulative evidence has also indicated that a number of genetic loci are associated with susceptibility to SSc-ILD, including CTGF (also known as CCN2, encoding connective tissue growth factor), CD247 and IRF5 (29–32). Fingerlin et al. reported that two HLA alleles in the high linkage disequilibrium are associated with pulmonary fibrosis (DRB1 * 15:01 and DQB1 * 06:02) (33, 34). These susceptibility genes are similar to the previous ILD-related loci associated with PM/DM (34–36). A list of CTD-ILD susceptibility genes currently identified in the literature is shown in the Table 1.

There are epigenetic mechanisms including DNA methylation, post-translational histone modification, and non-coding RNA in IPF. The differences in their DNA methylation pattern may influence the expressions of many target genes and microRNAs (miRNAs), as well as the regulatory sites of genes involved in IPF (53, 54). Based on comparative analysis of genome-wide DNA methylation together with gene expression patterns in lung tissues from IPF patients and normal controls, Sanders et al. demonstrated that ZNF467 and CLDN5 with hypermethylation are down-regulated, whereas TP53INP1 and DDAH1 with hypomethylation are up-regulated in IPF (55). Studies on histone modifications mainly revealed the involvement of epithelial-mesenchymal transition (EMT), apoptosis, and the prostaglandin E2 pathway (56). Histone deacetylase inhibitors can eliminate the differentiation of fibroblast-myofibroblasts induced by transforming growth factor-β1 (TGF-β1), restore the expression of surfactant protein-C in alveolar epithelial type II cells, and mitigate bleomycin-induced pulmonary fibrosis (57, 58). Histone deacetylase inhibition can also increase Fas expression, which exhibited low level expression in fibroblasts from both IPF patients and mice with experimental pulmonary fibrosis, and restore sensitivity to Fas-mediated apoptosis, indicating the key role of histone modification in the development of anti-apoptotic fibroblasts (59). Changes in miRNA profiles have been observed in IPF patients and mouse models of fibrosis, including the down-regulation of some microRNAs, such as let-7, mir-29 and mir-30, members of the miR-200 family, and upregulation of miRNAs, such as mir-155 and mir-21. Regulating the expression
Table 1 | Susceptibility genes in CTD-ILD.

| Disease   | Susceptibility genes                                                                 |
|-----------|-------------------------------------------------------------------------------------|
| RA-ILD    | DRB1*16:02, DRB1*15:02 (37-39) TERT, RTEL1, PARN or SFTPC (26) MUC5B (3)           |
| SSc-ILD   | HLA-B*52, HLA-C*06, DRB1*11 (40-42) DBP*03:01, DRB1 (43, 44) CD226, MMP12, SFTPB, CTGF, HGF, IFAK1, TCRBV, INF5 (29, 45-51) CD247 (30, 31) |
| PM/DM-    | DRB1*03, DRB1*01:01, DRB1*04:05 (35, 36)                                             |
| ILD       | DQB1*06:02 (34)                                                                     |
| CTD-ILD   | TERC, TERT (52)                                                                     |

TERT, telomerase reverse transcriptase; RTEL1, telomere-elongation helicase-1; PARN, poly(A)/poly(U)-specific ribonuclease desadenylase nucleases; SFTPC, surfactant protein C; MUC5B, recombinant Mucin 5 Subtype B; HLA, Human Leukocyte Antigen; CD, clusters of differentiation; MMP, matrix metalloproteinase; SFTPB, surfactant protein B; CTGF, connective-tissue growth factor; HGF, hepatocyte growth factor; IFAK, IL-1 receptor-associated kinase; TCRBV, T-cell receptor-β variable; IRF5, recombinant interferon regulatory factor 5; TERC, telomerase RNA component; TERT, telomerase reverse transcriptase.

Environmental Factors

Multiple environmental factors including gastroesophageal reflux disease (GERD), infections (7, 65), environmental chemicals, toxic substances, drugs (66–68), and tobacco smoke are associated with inflammatory lung injury (8, 69, 70). The prevalence of GERD in ILD can be as high as 94% (71–73). Animal studies have shown that chronic aspiration leads to pulmonary fibrosis (74). It is postulated that GERD-associated chronic micro-aspiration induces repetitive lung injury, resulting in pneumonitis, increased epithelial permeability, fibrotic hyperplasia, and ultimately pulmonary fibrosis (75). A murine model of aspiration-induced lung injury model exhibited extensive collagen deposition by the second week (76), and revealed reflux containing bile acids, elevated TGF-β levels, and prominent fibroblast proliferation (77). On the contrary, meta-regression analysis adjusted for smoking suggested chronic micro-aspiration in GERD is not associated with IPF (78). In addition to the contribution from acidic stomach contents, Helicobacter pylori in gastric juice can also cause lung injury, and thereby, promote progressive pulmonary fibrosis (79, 80).

Although Epstein-Barr virus is a prime suspect, other viruses and bacteria (e.g., retroviruses, parvoviruses, mycobacteria, Mycoplasma species, and Borrelia species) have also been implicated in inflammatory lung injury (7).

Particulate matter and toxic chemicals in tobacco smoke can activate immune cells, recruit inflammatory cells, and lead to the influx of various immune cells into the lungs, and this in concert can eventually lead to ILD (81, 82). However, the effect of smoking on CTD-ILD is unclear. Among various autoimmune diseases, RA is most definitely associated with smoking. Epidemiological studies have demonstrated that people exposed to tobacco smoke are at a higher risk of developing seropositive RA, and in predisposed individuals, smoking can promote the production of anti-cyclic citrullinated peptide (anti-CCP) antibodies (83–85). Notably, increased prevalence of emphysema and decreased survival have been noted in patients with SSc who smoke heavily, indicating the adverse effects of smoking in SSc (86–88).

More than 600 drugs have been reported to cause severe pulmonary injury (See pneumotox.com for a list of drugs that have been reported to cause lung toxicity). Multiple drugs used in treating cardiovascular diseases, anti-inflammatory, antimicrobial, and cancer immunotherapies as well nonbiologic and biologic disease-modifying anti-rheumatic drugs (DMARDs) have also been associated with severe lung injury (89). Anti-rheumatic drug-induced ILD (DILD) is not uncommon and can be driven via dose-dependent toxicity and immune-mediated allergic reaction (90). Risk factors of DILD include genetic susceptibility (91), age, sex, smoking, underlying lung disease such as pre-existing ILD, bronchiectasis, chronic obstructive pulmonary disease, dosage of drugs, and interactions with concomitant drugs and previous treatment, such as chest radiotherapy (68, 92, 93). Clinically, it is difficult to distinguish DILD from other interstitial pneumonias. Multiple imaging patterns can result from the same drug, and vice versa (68). Similarly, it is challenging to diagnose DILD due to presenting signs and symptoms that are often very similar to other ILDs.

The diagnosis of DILD is based on the following: (a) an exposure to the causative agent and presenting concomitant respiratory signs and symptoms which are consistent with previous reports, (b) ruling out other causes of lung damage including infection, cancerous lymphangitis, radiotherapy-induced pneumonitis, congestive heart failure, and exacerbation of pre-existing ILD, (c) alleviation of symptoms after discontinuation of the offending drug and relapse after reapplication. Rheumatologists may face several challenging clinical scenarios including the development of initial symptoms after drug withdrawal, or continued aggravation of clinical symptoms despite drug discontinuation. In addition, when a patient develops ILD during the treatment of a rheumatologic disorder, it is difficult to determine whether it is drug-induced or whether it is complicated by CTD. Similarly, when CTD-ILD patients progress or worsen during treatment, it is difficult to determine whether this is due to a drug side effect or the natural progression of disease.

Importantly, clinicians need to be aware of what medications are associated with DILD. The main nonbiological DMARDs include gold (94, 95), penicillamine (96), sulfasalazine (97), tacrolimus (98, 99), methotrexate (MTX) (93, 100–102), and leflunomide (103–105), and the biological agents mainly include anti-TNF, anti-CD20, and cytokine monoclonal antibodies (106, 107). Although MTX-induced ILD is well-established by many studies, there is some emerging conflicting evidence suggesting no association between MTX and RA-ILD (108). For example, a study of MTX use and the risk of ILD in RA patients demonstrated that there was no further increase in risk associated with MTX.
treatment (109). Other studies have also reported similar findings suggesting that MTX may delay the onset of ILD (110, 111). However, the overall picture and recommendation indicates that exposure to any of the aforementioned drugs could potentially lead to DILD. Therefore, the alert clinician must be aware of this possibility because early recognition could lead to the earlier initiation of therapy.

**Immunological Factors**

Both innate and adaptive immune system are potential culprits for the pathogenesis of CTD-ILD. For example, B cells contribute to autoimmune ILD (112) with studies showing the presence of extensive B cell infiltrations in lung tissue samples of SSc-ILD patients (9). Compared with IIP, RA-ILD is distinguished by its prominent increase in CD4+ cells and follicular B cell hyperplasia in the lung (113, 114). In patients with RA-ILD and SSc-ILD, T cells release fibrogenic mediators which subsequently stimulate fibroblasts and prime the fibrotic response (115). In SSc-ILD, alveolar macrophages become M2 polarized upon induction by the Th2 cytokines IL-4 and IL-10, suggesting that the M2/Th2 pathway is involved in the pathogenesis and development of SSc-ILD (116). Autoantibodies are also associated with CTD-ILD, with some antibodies occasionally related to the course and severity of the disease, reinforcing the notion that humoral immunity is involved in the pathogenesis of CTD-ILD (117, 118). This is discussed in greater detail in the CTD-ILD related autoantibody section below. Toll-like receptors (TLRs), key components of innate immunity, have multi-faceted effects on ILD in patients with CTD. TLRs have been proposed as markers of ILD progression (10). Correlation studies showed that TLR2 (119) and TLR9 (120) are profibrotic while TLR3 (121) is anti-fibrotic in pulmonary fibrosis. On the other hand, TLR4 can be either profibrotic (122) or anti-fibrotic (123) depending on the micro-environment. TLR2, TLR3 mRNA in bronchoalveolar lavage fluid (BALF) T-lymphocytes and peripheral blood monocytes, are over-expressed in CTD-ILD compared with healthy controls, suggesting that TLRs may be involved in the pathogenesis of CTD-ILD (124–126). The contribution of other innate players on CTD-ILD remains to be explored. Understanding the mechanistic roles of immune cell activities in CTD-ILD will help in the development of innovative and novel therapeutic approaches.

In genetically predisposed individuals, the pathogenesis of CTD-ILD involves recurrent alveolar injury and dysfunctional healing which are key causative mechanisms in the development of pulmonary fibrosis. Pulmonary fibroblasts are activated to produce extracellular matrix as inflammatory cells enter and infiltrate the lung interstitial and alveolar spaces. This leads to an imbalance of collagen formation and degradation, resulting in collagen over-accumulation in the lung (127). Epithelial and mesenchymal cells, as well as components of the innate and adaptive immune system, lead to a favorable microenvironment that promotes disease pathogenesis (128). These factors together, contribute to the chronic inflammation, gradual destruction of functional lung parenchyma, replacement by collagen, thus, ultimately leading to pulmonary fibrosis, respiratory failure, and early mortality.

**CLINICAL CHARACTERISTICS OF CTD-ILD**

Clinical manifestations of CTD-ILD include constitutional and respiratory symptoms, but these are rather non-specific. The common constitutional symptoms include fatigue, fever, and weight loss. The most common respiratory symptoms include exertional dyspnea, exercise intolerance, and dry (or non-productive) cough with slow progression over the time. Other concomitant symptoms may include chest pain, palpitations, tachypnea, and hemoptysis. In addition to pulmonary involvement, CT-ILD can also involve the mucocutaneous, musculoskeletal, neurological, gastrointestinal, cardiac, and hematologic systems.

Generally speaking, compared with IIP, CTD-ILD patients are more likely to be younger, female, and non-smokers. However, the exact frequency of CTD-ILD is not known. Although the incidence and prevalence vary between studies, it is estimated that 10 to 90% of patients with CTD will have evidence of pulmonary involvement during their lifetime. The types of pulmonary manifestations may vary by underlying CTD diagnosis (Table 2). The prevalence and mortality of ILD for each CTD are different, and the prevalence of ILD secondary to various CTDs varies as follows: 1 to 15% in SLE (106), 6.5 to 33% in RA (107, 108), 19.9 to 86% in PM/DM (109, 110), 86% in anti-Jo-1 positive patients (111), 40 to 91% in SSc (112, 113), 47 to 90% in MCTD based on radiologic feature (108, 114), and 9 to 20% in SS (115). Related reports indicate the mortality of ILD is 20% in RA-ILD (116, 117), 12 to 44% in PM/DM (118), and a 10-year mortality of up to 40% in SSc (119). In patients with RA and SSc, the 5-year mortality is 3-fold higher than that without ILD (120, 121).

**HISTOLOGICAL CLASSIFICATION OF CTD-ILD**

Histologically, CTD-ILD can be divided into 7 types including: usual interstitial pneumonia (UIP), nonspecific interstitial pneumonia (NSIP), desquamative interstitial pneumonia (DIP), respiratory bronchiolitis (RB), organizing pneumonia (OP), diffuse alveolar damage (DAD), and lymphoid interstitial pneumonia (LIP) (129, 130). These histological classifications provide a more comprehensive diagnosis of CTD presenting with ILD. We note that NSIP is the most common histopathologic type in CTD-ILD (with the exception of RA), however, UIP is the most common in IIP (131). In addition, the frequency and severity of fibroblastic lesions in CTD-ILD is lower than IPF-UIP (132). We also note that the coexistence of UIP and NSIP patterns is one of the most significant features that distinguishes CTD-UIP from IPF-UIP (133). The frequency of ILD pathological subtype from different underlying CTDs is shown in Table 2 (134–137). Although the pathological classification of CTD-ILD is identical to that of IIP, some histopathologic features such as extensive plasma cell infiltration, increased lymphoid aggregates, and more germinal centers are considered to be characteristic histologic
features of CTD-ILD as compared with IIP (138–140). Indeed, the clinical characteristics, therapeutic response to GC and immunosuppressive agents, and prognosis of CTD-ILD vary according to the pathological subtypes (Table 3).

**IMAGING FEATURES OF CTD-ILD**

Radiologically, high resolution computed topography (HRCT) scans can be effectively used to diagnose and identify disease and assess disease improvement or progression. CTD-ILD may manifest as a focal or a diffuse pulmonary abnormality, especially at the periphery of the lung, such as reticulation, ground-glass opacities (GGOs) (which refers to focal or diffuse veil-like opacification of the lung), and nodules. Imaging findings of the different kinds of pulmonary lesions vary with specific diseases and histopathologic patterns observed (151, 152). In addition to their respective characteristic imaging manifestations, certain radiological clues support the diagnosis of CTD-ILD (Table 3 and Figure 2). For example, (a) In the combined NSIP-OP pattern (130, 153), CTDs such as idiopathic inflammatory myopathies (IIMs) or anti-synthetase syndrome (ASS) should be suspected when the fibrosis at the lung bases overlaps with an OP pattern. (b) In the combined DAD-IIP pattern, when the DAD is superimposed on another IIP pattern it may indicate the presence of CTD. Sometimes ASS manifests as acute respiratory failure with DAD superimposed on underlying IIP, however, this is not specific to ASS (151, 154). Atypical interstitial pneumonia may be due to unclassifiable or mixed imaging findings (155).

Chung et al. compared the CT manifestations of CTD-UIP and IPF-UIP, and found that there are three imaging manifestations with high specificity but low sensitivity for CTD-ILD, including (i) the “anterior upper lobe” sign and concomitant lower lobe involvement, (ii) “exuberant honeycombing” sign constituting greater than 70% of fibrotic portions of the lung, and (iii) “straight-edge” sign indicating lung basal fibrosis with sharp demarcation in the craniocaudal plane (155).

Finally, some extrapulmonary signs on HRCT support the diagnosis of CTD-ILD, such as esophageal or pericardial abnormalities, features of pulmonary arterial hypertension, evidence of airway disease, findings suggestive of bone and joint involvement, and soft-tissue calcifications (156).

**CLINICAL SIGNIFICANCE OF CTD-ILD RELATED AUTOANTIBODIES**

There are multiple autoantibodies in the sera of patients with CTD, many of which are associated with interstitial lung injury (Table 4). Among the SSc-ILD-related antibodies, antitopoiso merase antibodies are more likely to be associated with pulmonary fibrosis, while anti-RNA polymerase III antibodies are less likely to be associated with pulmonary fibrosis (157). Other antibodies have also been linked to increased lung fibrosis risk in SSc, including anti-U11/U12 ribonucleoprotein (RNP) antibodies, or anti-Th/To-RNP antibodies (158). Anti-U11/U12 RNP may be related to the severity of ILD (159–162). The correlation between anti-Scl-70 and the severity of ILD is unclear, however, anti-Ro52 antibody is associated with ILD and poor prognosis in SSc. The ANA of nucleolar pattern is also associated with pulmonary fibrosis in patients with SSc whereas anticentromere antibodies (ACA) are not. ANA patterns can be used to predict the risk of pulmonary fibrosis in patients with SSc (163).

In patients with autoimmune inflammatory myopathy, myositis-specific autoantibodies (MSAs) and myositis-associated antibodies (MAAs) are associated with IIM-ILD, and those with anti-Ku antibodies have a higher risk of lung involvement (161). Single factor Cox hazards analysis showed that the presence of anti-RNA polymerase III antibodies (ARS) indicates a better prognosis, and the presence of anti-synthetase antibodies might be used as a prognostic marker for PM/DM ILD patients. Sabbagh et al. discovered that patients with adolescent myositis with anti-Ro52 were more likely to develop ILD, have more severe

---

**TABLE 2 | Characteristics of lung involvement in different CTD-ILD.**

| Manifestation | RA | SSc | SS | SLE | PM/DM | MCTD |
|--------------|----|-----|----|-----|-------|------|
| Airways disease | ++ | –– | ++ | –– | +     | –    |
| ILD | ++ | +++ | ++ | + | +++ | +++ |
| NSIP | ++ | +++ | ++ | + | ++ | ++ |
| UIP | +++ | + | + | + | + | + |
| OP | + | – | – | – | – | – |
| DAH | + | + | + | + | + | – |
| Pleural disease | ++ | – | + | + | ++ | – |
| Vascular disease | + | +++ | + | + | + | + |
| Pulmonary hypertension | + | +++ | + | + | + | + |
| Parenchymal nodules | + | – | – | – | – | – |
| Respiratory muscle disease | – | – | + | + | ++ | + |
| Aspiration pneumonia | – | +++ | – | – | + | + |

NSIP, nonspecific interstitial pneumonia; UIP, usual interstitial pneumonia; OP, organizing pneumonia; DAD, diffuse alveolar damage; AIP, acute interstitial pneumonia; LIP, lymphoid interstitial pneumonia; DAH, diffuse alveolar hemorrhage.

Prevalence of each manifestation is expressed as:

–, no prevalence; +, low prevalence; ++, medium prevalence; +++, high prevalence.
disease, and have a worse prognosis (164). A related study demonstrated that anti-Ro52 antibodies and anti-Jo1 antibodies are usually present together (165), and anti-Ro52 antibody titers correlate with ILD severity (166). Compared to anti-Jo1 autoantibodies alone, adult patients with both autoantibodies were more prone to severe ILD, poorer response to various immunosuppressive drugs, and lower survival rates (167–169).

Specifically targeted to scaffold attachment factor B (SAFB), anti-SAFB antibodies were detected in a small number of patients with SSc and/or PM/DM, and ILD. Anti-SAFB antibodies may be a novel CTD-related autoantibody associated with ILD (170).

Elevation of RF and anti-CCP antibodies in the serum and BALF are considered risk factors for RA-ILD (171–174). While anti-SSA/Ro and anti-SSB/La are associated with SS-ILD, it is interesting that the specificity of anti-La antibodies in lung involvement is higher than that of anti-Ro antibodies. Anti-U1-RNP, immune complex, complement C3 factor, and CH50 are highly expressed in MCTD-ILD. Anti-Ro52 antibodies are associated with MCTD-ILD (175). Anti-endothelial cell antibodies (AECAs) are associated with a high incidence of pulmonary fibrosis and severe diffusion abnormalities (176). In addition to these autoantibodies, other ILD-associated CTD autoantibodies and serological immune markers are listed in Table 4 (177).

### IDENTIFYING HIGH-RISK PATIENTS

Rheumatologists should be vigilant about CTD-ILD, including the timely identification of high-risk patients. ILD is characterized by non-productive cough, fever, a gradual onset of exertional dyspnea, and fine bibasilar inspiratory crackles (“velcro” crackles). These signs and symptoms are non-specific.

### TABLE 3 | Clinical Characteristics, Response to Therapy and Prognosis of CTD-ILD Subtypes.

| Pathological Subtype | Course | Clinical Manifestations | Imaging Findings | Pathologic Features | Therapeutic Effects to GC and IMS | Prognosis |
|----------------------|--------|-------------------------|------------------|--------------------|----------------------------------|-----------|
| AIP (141)            | Acute: days to weeks | Fever, cough and progressive severe tachypnea | Bilateral ground-glass opacities and/or airspace consolidation | Diffuse alveolar damage | Yes | 75% mortality in 6 months |
| OP (142–144)         | Acute/subacute: days to months | Fever, cough and dyspnea | Bilateral patchy peripherally located consolidations or ground glass opacities. | An excessive proliferation of fibrous tissue within the alveolar sacs and alveolar ducts | Yes | Spontaneous remissions are seen in about 50% of mild cases. Patients demonstrate a rapid symptomatic response to treatment and up to 80% achieve complete cure |
| UIP (145–147)        | Chronic: months to years | Slowly progressive dyspnea and nonproductive cough | Honeycombing with a peripheral predominance | Patchy dense fibrosis causing remodeling of lung architecture | No | 5- and 10-year survival are 43% and 15%, respectively, median survivals from the time of diagnosis is about 3 years |
| NSIP (147, 148)      | Chronic: months to years | An insidious onset of shortness of breath over several months, accompanied by a cough | Bilateral ground-glass opacities in a basal and peripheral distribution | A temporally homogeneous inflammatory and fibrosing interstitial process | No | 86%-92% 5-year survival and 26%-40% 10-year survival rates |
| LIP (149, 150)       | Chronic: months to years | Progressive dyspnea and dry cough | Thickened bronchovascular bundles, nodules of varying sizes, and ground-glass opacities | Diffuse interstitial lymphocytic infiltrates with widened interlobular and alveolar septae | Yes | 5-year mortality is 33% to 50% for all types of LIP despite treatment, with reported median survival times ranging from 5 years to 11.5 years |

GC, glucocorticoid; IMS, immunosuppressive agents.
and can be seen in a variety of pulmonary and/or heart diseases, and approximately 5% of patients have no symptoms when ILD is serendipitously diagnosed. One important consideration involves patients with negative autoantibodies and no extrapulmonary immune features who are eventually diagnosed with CTD-ILD after long-term follow-up. Since diagnosis of these patients can be challenging and delayed, regular assessments are required during clinic follow-ups to make the correct diagnosis. In a study on 1,044 Chinese CTD-ILD patients, 43.8% of them had a negative autoantibody serological test at the time of initial admission, however 25.1% seroconversions and 18.7% persistent negatives were found on subsequent follow-ups. In the latter group, most of these patients were finally diagnosed with CTD-ILD because of their emerging extrapulmonary features and/or need for lung biopsy (178).

Pulmonary dysfunction mainly manifests as a restrictive pattern with a decrease in total lung capacity (TLC), forced vital capacity (FVC), residual volume (RV), functional residual capacity (FRC), and diffusion capacity of carbon monoxide (DLCO). These pulmonary function test (PFT) findings reflect a restrictive ventilator defect due to pulmonary interstitial fibrous tissue hyperplasia leading to increased diffusion distance, and decreased diffusion capacity.

An emerging phenotype called "progressive fibrosing-ILD" (PF-ILD) that is characterized by significant decline in FVC (relative decline of ≥5-10%) and DLCO (relative decline of ≥5-15%) over a period of time ranging between 6 to 24 months, is associated with increased mortality (179, 180). Other criteria included worsening symptoms and increased fibrotic changes on HRCT (181). CTD-ILD can present with a PF-ILD phenotype if they meet the above criteria (179, 181). A recent decline in FVC and DLCO are independent predictors of decreased survival rate in SSc-ILD (157, 182-184).

On thoracic imaging, loss of lung volume, parenchymal reticulations, and GGOs are common. Typical pulmonary HRCT findings in patients with CTD-ILD include GGOs, fiber strips, sub-pleural interlobular septal thickening, small nodules, traction bronchiectasis, subpleural arc shadow, honeycomb lung changes (mainly concentrated in the middle and lower lungs), and cystic formations. Some specific imaging features are associated with an increased likelihood of progression and risk of death in interstitial lung abnormalities. For example, an increased extent of lung fibrosis on HRCT and definitive signs of fibrosis (e.g. pulmonary parenchymal architectural distortion) predict the highest risk of progression. Subpleural reticular marks suggest increased likelihood of progression as well as honeycombing and traction bronchiectasis, while centrilobular nodules may suggest a lower likelihood of progression. Both 'probable UIP' and 'UIP patterns' are related to increased risk of death (185). In addition, disease progression on imaging is associated with increasing age and MUC5B genotype copies (186, 187). Interestingly, computer-based computed tomography analysis (CALIPER) indicates that pulmonary vessel volume is an independent predictor of mortality in CTD-ILD patients (188).

Serum markers have also been investigated in the diagnosis and prognosis of ILD (189, 190). The presence of the same biomarkers suggests that CTD-ILD and IPF share a common pathophysiological process or mechanism (191, 192). In CTD-ILD, different biomarkers have been associated with worse outcome such as Krebs von den Lungen-6 (KL-6), cancer antigen 19-9 (CA 19-9), cancer antigen 125 (CA 125), vascular cell adhesion molecule-1 (VCAM-1), and C-X-C motif chemokine ligand 13 (CXCL13) (193). SSc-ILD prognostic biomarkers included, in addition to the above biomarkers, surfactant protein-D (SP-D), surfactant protein-A (SP-A), chitinase-3-like protein 1 (YKL-40), matrix metalloproteinases 12 (MMP12), tissue inhibitor of metalloproteinase-1 (TIMP-1), 16-kDa Clara cell secretory protein (CC16), (Tenascin C), C-C motif chemokine ligand 2 and 8 (CCL2 and CCL18), interleukins 6 and 2 (IL-6 and IL-2), C reactive protein (CRP), C-X-C motif chemokine ligand 4 and 10 (CXCL4 and CXCL10), and fractalkine (CX3CL1) (193).

Most importantly, rheumatologists must consider the clinical characteristics and radiographic findings of their patients and use serum biomarkers to aid their diagnostic work-up, and where appropriate, help in prognostication. KL-6 has the strongest value in diagnosing IPF and CTD-ILD, followed by SP-D, and MMPs as the most meaningful tools for IPF diagnosis. KL-6, SP-D, and chemokine ligand 18 (CCL18) have a high sensitivity but are not specific in diagnosing SSc-ILD, and CCL18 can predict

### Table 4 | Autoantibodies and serological immune markers associated with CTD-ILD.

| PM/DM | SSc | RA | SS | MCTD |
|-------|-----|----|----|------|
| **Autoantibodies and serological immune markers** | | | | |
| MSAs | anti-Scl-70 | RF | Anti-SSA/Ro | Anti-U1RNP |
| anti-Jo-1 | anti-U3RNP | Anti-CCP | Anti-SSB/La | |
| anti-PL-12 | anti-U11/U1RNP | | | |
| anti-PL-7 | anti-RfxBL12 | | | |
| anti-KS | anti-ElF2B | | | |
| anti-OJ | anti-PM-Scl | | | |
| anti-Ej | anti-U1RNP | | | |
| anti-Zo | anti-cardiolipin | | | |
| anti-Ku | anti-Tr/To | | | |
| anti-MAA5 | anti-Ro52 | | | |
| MAAs | anti-NOR90 | | | |
| anti-Ro52/60 | | | | |
| anti-U1RNP | nucleolar ANA | | | |
| ANCA | | | | |

MSAs, myositis-specific autoantibodies; MDA5, melanoma differentiation-associated gene 5; MAAs, myositis-associated antibodies; ANCA, anti-neutrophil cytoplasmic antibodies; RF, rheumatoid factor; Anti-CCP, anti-citrullinated peptide antibodies; CIC, circulation immunity compound.
the deterioration of IPF and SSc-ILD where CCL18 has a higher predictive value (194–208).

**ASSESSMENT AND TREATMENT OF CTD-ILD**

The correct and timely diagnosis of CTD-ILD is necessary in order to deliver appropriate therapy. Once the diagnosis of CTD-ILD is established and extent of disease progression is assessed, then prognosis can be determined. An individualized treatment regime can then be initiated with regular clinic follow-ups (3, 209, 210). Indications to use GC and immunosuppressive agents depends on the primary disease, systemic activity, reversibility, and ILD clinical course. ILD can be divided into main IIP, rare IIP, and unclassified IIP (211). Main IIP can be further sub-divided into acute IIP (days to weeks), mainly AIP and OP; subacute IIP (weeks to months), mainly OP; and chronic IIP (months to years), mainly UIP and NSIP. The rare IIP is typically LIP. Patients with acute and subacute phase IIP need timely initiation of GC treatment combined with immunosuppressive therapy. For patients with chronic phase IIP such as honeycombed lung, high-dose GC and immunosuppressive therapy may not be beneficial. In this case, anti-pulmonary fibrosis treatment such as pirfenidone and nintedanib (212–214) may be considered.

The prognosis of CTD-ILD depends on ILD classification. The more urgent the course is, the better the effect of GC and immunosuppressive agents. On the other hand, the slower the course of the disease, as in NSIP and UIP, the poorer the efficacy of GC and immunosuppressive agents and the worse the prognosis. Considering the selection of immunosuppressive agents, there is currently no uniform management guideline for CTD-ILD. Rheumatologists should carefully consider the actual situation of each patient according to their underlying CTD, disease severity, the rate of disease progression (215–218) when selecting immunosuppressive agents [i.e. cyclophosphamide (CYC) (219–222), mycophenolic mofetil (223–225), azathioprine (226, 227), cyclosporine (228), tacrolimus (229, 230), and CD20 monoclonal antibody (231, 232)].

Several new therapeutic agents have been reported for the treatment of CTD-ILD, including Tripterygium wilfordii Hook F (233), tocilizumab, and abatacept. A clinical study reported the therapeutic efficacy of Tripterygium wilfordii Hook F as being comparable to CYC in the treatment of SSc-ILD when used only for maintenance therapy, but not for induction therapy (233). Biologics are also increasingly becoming available to treat ILD. Based on the rationale that elevated circulating IL-6 is predictive of progression in SSc-ILD (234), and the promising results from clinical trials (235–237), the FDA has approved tocilizumab in adult patients with SSc-ILD (218). Current evidence also indicates the promising efficacy and safety of abatacept in treating RA-ILD patients (238, 239).

In terms of anti-fibrosis therapy, the United States FDA has approved nintedanib, an inhibitor of multiple tyrosine kinases, for use in CTD-ILD with PF-ILD phenotype and SSc-ILD (218, 240). Two large randomized clinical trials (SENSCIS and INBUILD) showed that nintedanib reduced the annual rate of loss of FVC (212, 240). CTD-ILD with the PF-ILD phenotype and SSc-ILD patients who still exhibit disease progression after being treated with MMF or CYC may benefit from the addition of nintedanib to standard treatment (212, 240, 241). Although a pilot study has shown that administration of pirfenidone was associated with a reduction in dyspnea and an increase in vital capacity in SSc-ILD (242), other studies have not demonstrated a significant effect of pirfenidone (243), and therefore, the evidence for pirfenidone in these groups is less convincing (244). Other treatments include IVIG, plasmapheresis (245), and anti-reflux drugs. For end-stage or refractory cases, two promising novel therapeutic strategies such as autologous hematopoietic stem-cell transplantation and lung transplantation may be considered (246).

Clinical deterioration during routine follow-up should prompt the treating rheumatologists to consider the possible underlying causes: Acute exacerbation of CTD-ILD? Drug-induced ILD? Infection? Of note, when considering whether a patient’s presentation is due to acute exacerbation of CTD-ILD or infection, it is critically important to rule out infection before initiating immunosuppressive treatment (247–252). The exact cause of a patient’s exacerbation should be determined as expeditiously as possible. However, it is also possible that multiple concomitant factors are causing the exacerbation. Notably, it is important to recognize that infections and acute exacerbation of CTD-ILD can mimic one another, can coexist, and can promote each other (65, 248, 253–255).

A comprehensive clinical evaluation is required including: (a) evaluation of the patient’s occupation or living environment, (b) analysis of current or prior medication use, (c) systemic analysis of the patient’s symptoms, signs, imaging characteristics, and infection screening, and (d) evaluation of the patient’s immune function status (including neutrophils, humoral immunity, cellular immunity levels and functional status). The first step is to remove any suspicious drugs, then followed by initiation of specific therapy such as GC (as long as infection has been ruled out). If the diagnosis is still uncertain after this evaluation, for patients with mild disease, the diagnosis should be confirmed with more extensive or invasive examination. If the diagnosis remains elusive, then antimicrobial therapy may be considered first. If this approach is ineffective, then empiric treatment with a GC may be considered. For critically ill patients, treatment with combination antibiotics and a GC is generally recommended albeit clinical evidence is limited.

Supportive care including cessation of cigarette smoking, use of supplemental oxygen, annual influenza vaccination, and pneumococcal vaccination, should all be considered. In addition to treating the underlying disease, it is also necessary to treat comorbidities such as GERD, pulmonary hypertension, and sleep apnea. Consultation with a gastroenterologist, cardiologist, and pulmonologist is often necessary to formulate an appropriate treatment plan for the patient. Prognosis is related to the patient’s underlying disease, type of ILD, response to treatment, related comorbidities, as well as the patient’s education level and compliance with medical therapy.
(Table 3). The treating rheumatologist needs to actively educate patients, effectively communicate with patients and their families (including end-of-life considerations), and work with patients to develop individualized treatment plans.

FUTURE DIRECTIONS

The clinical incidence of CTD-ILD is high. Each type of CTD-ILD has its distinct clinical characteristics, therapeutic response, and prognosis. In general, the lung is one of the important organs involved in CTD where symptoms can first arise and where lung function is an independent prognostic indicator in CTD. In light of the heterogeneity and complexity of CTD-ILD and its clinical manifestations and presentations, a multi-disciplinary collaborative effort with other clinical specialists is often necessary to further our understanding of CTD-ILD and to develop individualized treatment plans.

Our collective goal is to improve the early diagnosis and treatment of CTD-ILD in order to improve the prognosis and survival of patients. Looking into the near future, advanced research technologies using high-throughput genomics, proteomics, and metabolomics together with artificial intelligence will further pave the way and provide insight in identifying relevant mechanistic pathways and molecular targets for drug development and disease interventions.

AUTHOR CONTRIBUTIONS

TS, XS, PL, and ZS wrote the main manuscript text and prepared all figures. XL and JS provided the image data. SY, WZ, SA, AZ, PL, and ZS jointly supervised this work. All authors contributed to the article and approved the submitted version.

FUNDING

The Key Research and Development Projects of Anhui Province (1804h08020228).

REFERENCES

1. Crestani B. The Respiratory System in Connective Tissue Disorders. Allergy (2005) 60:715–34. doi: 10.1111/j.1398-9995.2005.00761.x
2. Mira-Avendano I, Abril A, Burger CD, Dellapilla PF, Fischer A, Gotway MB, et al. Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. Mayo Clin Proc (2019) 94:309–25. doi: 10.1016/j.mayocp.2018.09.002
3. Mathai SC, Danoff SK. Management of Interstitial Lung Disease Associated With Connective Tissue Disease. BMJ (2016) 352:h6819. doi: 10.1136/bmj.h6819
4. Korsten P, Konig MF, Tampe B, Mirsaedi M. Interstitial Lung Disease in the Context of Systemic Disease: Pathophysiology, Treatment and Outcomes. Front Med (2020) 7:1138. doi: 10.3389/fmed.2020.644075
5. Sebastiani M, Faverio P, Manfredi A, Cassone G, Vacchi C, Stainer A, et al. Interstitial Pneumonia with Autoimmune Features: Why Rheumatologist-Pulmonologist Collaboration is Essential. Biomedicines (2020) 9:17. doi: 10.3390/biomedicines9010017
6. Ifuhe P, Lee JS, Ebstein E, Furukawa H, Dobrinskikh E, Gazal S, et al. MUC5B Promoter Variant and Rheumatoid Arthritis With Interstitial Lung Disease. N Engl J Med (2018) 379:2209–19. doi: 10.1056/NEJMoa1801562.
7. Azadeh N, Limper AH, Carmona EM, Ryu JH. The Role of Infection in Interstitial Lung Diseases: A Review. Chest (2017) 152:842–52. doi: 10.1016/j.chest.2017.03.033
8. Kumar A, Cherian SV, Vassallo R, Yi ES, Ryu JH. Current Concepts in Pathogenesis, Diagnosis, and Management of Smoking-Related Interstitial Lung Diseases. Chest (2018) 154:394–408. doi: 10.1016/j.chest.2017.11.023
9. Lafyatry R, O’Hara C, Feghali-Bostwick CA, Matteson E. B Cell Infiltration in Systemic Sclerosis-Associated Interstitial Lung Disease. Arthritis Rheum (2007) 56:3167–8. doi: 10.1002/art.22847
10. Karampitsakos T, Woolard A, Bours D, Tsouvelakis A. Toll-Like Receptors in the Pathogenesis of Pulmonary Fibrosis. Eur J Pharmacol (2017) 808:335–43. doi: 10.1016/j.ejphar.2016.06.045
11. Stuart BD, Lee JS, Kozlitina J, Noth I, Devine MS, Glazer CS, et al. Effect of Telomere Length on Survival in Patients With Idiopathic Pulmonary Fibrosis: An Observational Cohort Study With Independent Validation. Lancet Respir Med (2014) 2:557–65. doi: 10.1016/s2213-2600(14)70124-9
12. Dai J, Cai H, Li H, Zhuang Y, Min H, Wen Y, et al. Association Between Telomere Length and Survival in Patients With Idiopathic Pulmonary Fibrosis. Respirology (2015) 20:947–52. doi: 10.1111/resp.12566
13. Snetselaar R, van Batenburg AA, van Oosterhout MFM, Kazemier KM, Roothaan SM, Peeters T, et al. Short Telomere Length in IPF Lung Associates With Fibrotic Lesions and Predicts Survival. PloS One (2017) 12:e0189467. doi: 10.1371/journal.pone.0189467
14. Newton CA, Batra K, Torrealba J, Kozlitina J, Glazer CS, Aravena C, et al. Telomere-Related Lung Fibrosis is Diagnostically Heterogeneous But Uniformly Progressive. Eur Respir J (2016) 48:1710–20. doi: 10.1183/13993003.02308-2016
15. Seibold MA, Wise AL, Speer MC, Steele MP, Schwartz DA. A Common Muc5b Promoter Polymorphism and Pulmonary Fibrosis. New Engl J Med (2011) 364:1503–12. doi: 10.1056/NEJMoa1103660
16. Zhang Y, Noth I, Garcia JGN, Kaminski N. A Variant in the Promoter of MUC5B and Idiopathic Pulmonary Fibrosis. N Engl J Med (2011) 364:1576–7. doi: 10.1056/NEJMct1103504
17. Fingerlin TE, Murphy E, Zhang W, Pelto AL, Brown KK, Steele MP, et al. Genome-Wide Association Study Identifies Multiple Susceptibility Loci for Pulmonary Fibrosis. Nat Genet (2013) 45:613–20. doi: 10.1038/ng.2609
18. Noth I, Zhang Y, Ma S-F, Flores C, Barber M, Huang Y, et al. Genetic Variants Associated With Idiopathic Pulmonary Fibrosis Susceptibility and Mortality: A Genome-Wide Association Study. Lancet Respir Med (2013) 1:309–17. doi: 10.1016/S2213-2600(13)70045-6
19. Bori R, Crestani B, Dieude P, Nunes H, Allanore Y, Kannengiesser C, et al. The MUC5B Variant Is Associated With Idiopathic Pulmonary Fibrosis But Not With Systemic Sclerosis Interstitial Lung Disease in the European Caucasian Population. PloS One (2013) 8:e70621. doi: 10.1371/journal.pone.0070621.
20. Horimasa Y, Ohshima S, Bonella F, Tanaka S, Ishikawa N, Hattori N, et al. MUC5B Promoter Polymorphism in Japanese Patients With Idiopathic Pulmonary Fibrosis. Respir Med (2015) 20:439–44. doi: 10.1111/resp.12466
21. Stock C, Sato H, Fonseca B, Bany W, Salome P, Adanali H, et al. Mucin 5B Promoter Polymorphism is Associated With Idiopathic Pulmonary Fibrosis But Not With Development of Lung Fibrosis in Systemic Sclerosis or Sarcoidosis. Thorax (2013) 68:436–41. doi: 10.1136/thoraxjnl-2012-201786
22. Lee MG, Lee YH. A Meta-Analysis Examining the Association Between the MUC5B Rs35705950 T/G Polymorphism and Susceptibility to Idiopathic Pulmonary Fibrosis. Thoraxjnl-2012-201786
23. Van DV, Joanne J, Snetselaar R, Kazemier KM, ten Klooster L, Grutters JC, et al. Effect of Muc5b Promoter Polymorphism on Disease Predisposition
and Survival in Idiopathic Interstitial Pneumonias. Respirology (2016) 21:712–7. doi: 10.1111/resp.12728

4. Newton CA, Oldham JM, Ley B, Anand V, Adeggunaye A, Liu G, et al. Telomere Length and Genetic Variant Associations With Interstitial Lung Disease Progression and Survival. Eur Respir J (2019) 53:1801641. doi: 10.1183/13993003.01614-2018

5. EVans CM, Fingerlin TE, Schwarz MI, Lynch D, Kuchte J, Warg L, et al. Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. Physiol Rev (2016) 96:1567–91. doi: 10.1152/physrev.00004.2016

6. Iuge PA, Borie R, Kannengiesser C, Gazal S, Dieude P. Shared Genetic Predisposition in Rheumatoid Arthritis-Interstitial Lung Disease and Familial Pulmonary Fibrosis. Eur Respir J (2017) 49:1602314. doi: 10.1136/annrheumdis-2017-ecdar.5237

7. Kelly CA, Saravanan V, Nisar M, Arthanari S, Woodhead FA, Price-Forbes AN, et al. Rheumatoid Arthritis-Related Interstitial Lung Disease: Associations, Prognostic Factors and Physiological and Radiological Characteristics—A Large Multicentre UK Study. Rheumatology (2014) 53:1676–82. doi: 10.1093/rheumatology/keu165

8. Doyle TJ, Dellaripa PF, Batra K, Frits ML, Iannaccone CK, Hatabu H, et al. Melanoma Differentiation Antigen-1-Induced Epithelial-Mesenchymal Transition in Human Bronchus Epithelial Cells Through Epigenetic Silencing of ZEB1. Clin Lung Insights Circ Respir Pulm Med (2015) 9:1–7. doi: 10.4137/ccrpm.s23283

9. Fingerlin TE, Zhang W, Yang IV, Ainsworth HC, Russell PH, Bluhmagen RZ, et al. Genome-Wide Imputation Study Identifies Novel HLA Locus for Pulmonary Fibrosis and Potential Role for Auto-Immunity in Fibrotic Idiopathic Interstitial Pneumonia. BMC Genet (2016) 17:74. doi: 10.1186/ s12863-016-0377-7

10. Chinoy H, Salwya F, Fertig N, Shephard N, Tait BD, Thomson W, et al. In Adult Onset Myositis, the Presence of Interstitial Lung Disease and Myositis Specific/Associated Antibodies are Governed by HLA Class II Haplotype, Rather than by Myositis Subtype. Arthritis Res Ther (2005) 8:R13. doi: 10.1186/ar1862

11. Gono T, Kawaguchi Y, Kuwana M, Sugitra T, Furuya T, Takagi K, et al. Brief Report: Association of HLA-DRB1*0101/*0405 With Susceptibility to Anti–Melanoma Differentiation–Associated Gene 5 Antibody–Positive Dermatomyositis in the Japanese Population. Arthritis Rheum (2012) 64:3736–40. doi: 10.1002/art.34657

12. Migita K, Nakamura T, Koga T, Eguchi K. HLA-DRB1 Alleles and Rheumatoid Arthritis-Related Pulmonary Fibrosis. J Rheumatol (2010) 37:205–7. doi: 10.3899/jrheum.090303

13. Furukawa H, Oka S, Shimada K, Tsujiya N, Tohma S. Genetics of Interstitial Lung Disease: Vol De Nuit (Night Flight). Clin Med Insights Circ Respir Pulm Med (2015) 9:1–7. doi: 10.4137/ccrpm.s23283

14. Shao et al. Mechanisms and Managements of CTD-ILD
59. Huang SK, Scruggs AM, Donaghy J, Horowitz JC, Zaslova Z, Przybranowski S, et al. Histone Modifications are Responsible for Decreased Fas Expression and Apoptosis Resistance in Fibrotic Lung Fibroblasts. Cell Death Dis (2020) 11:621. doi: 10.1038/celldis.2020.146

60. Pandit KV, Mislove J, Kaminski N. MicroRNAs in Idiopathic Pulmonary Fibrosis. Trans Res (2011) 157:191–9. doi: 10.1016/j.trsl.2011.01.012

61. Yang S, Banerjee S, de Freitas A, Sanders YY, Ding Q, Matalon S, et al. Participation of miR-200 in Pulmonary Fibrosis. Am J Pathol (2012) 180:484–93. doi: 10.1016/j.ajpath.2011.10.005

62. Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, John B, et al. Viruses in Idiopathic Pulmonary Fibrosis. Viruses and Exacerbation. Ann Am Thoracic Soc (2015) 12:5816–92. doi: 10.1513/ AnnalsATS.201502-088AW

63. Pottier N, Maurin T, Chevalier B, Puisségur M, Lebriand K, Roche-Vermeersant K, et al. Identification of Keratinocyte Growth Factor as a Target of microRNA-155 in Lung Fibroblasts: Implication in Epithelial-Mesenchymal Interactions. PloS One (2009) 4:e6718. doi: 10.1371/journal.pone.0006718

64. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, et al. miR-21 and Exacerbation of the Innate Immune Response to Chronic Aspiration in a Novel Rodent Model. J Exp Med (2010) 207:1589–97. doi: 10.1084/jem.20100035

65. Moore BB, Moore TA. Viruses in Idiopathic Pulmonary Fibrosis. Etiology and Exacerbation. Ann Am Thoracic Soc (2015) 12:5816–92. doi: 10.1513/AnnalsATS.201502-088AW

66. Rouzibeh C, Harari S, Caminati A, Antoniou KM. Smoking-Related Interstitial Pulmonary Pneumonia: A Review. Respir Res (2016) 21:57–64. doi: 10.1186/issn:12975

67. Caminati A, Graziano P, Sverzellati N, Harari S. Smoking-Related Interstitial Lung Diseases. Pathologica (2010) 102:525–36.

68. Tobin RW, Pope CE, Pellegrini CA, Emond MJ, J. Sillery and G. Raghu: Participation of miR-200 in Pulmonary Fibrosis. Am J Respir Crit Care Med (2016) 154:104–12. doi: 10.1164/rcrm.201603.1246

69. Skeoch S, Weatherly N, Swift AJ, Oldroyd A, Johns C, Hayton C, et al. DMARDS and Biologic Agents in Rheumatoid Arthritis: A Systematic Review. AnnalsATS.201502-088AW

70. Pandit KV, Milosevic J, Kaminski N. MicroRNAs in Idiopathic Pulmonary Fibrosis. Current Issues in Drug Discovery. In: Drug Induced Lung Injury Springer Nature Singapore Pte Ltd (2018). pp. 3–13.

71. Appel JZ, Lee SM, Hartwig MG, Li B, Hsieh C-C, Cantu E, et al. Characterization of the Innate Immune Response to Chronic Aspiration in a Novel Rodent Model. Respir Res (2007) 8:83. doi: 10.1186/1465-9921-8-87

72. Johansson KA, Stråmbäck I, Ravaglia C, Grutters JC, Valenzuela C, Mogulkoc N, et al. Antacid Therapy in Idiopathic Pulmonary Fibrosis: More Questions Than Answers? Lancet Respir Med (2017) 5:98–11. doi: 10.1016/S2213-2690 (17)30219-9

73. Amigon I, Bellani G, Scanziani M, Masson S, Bertoli E, Radaelli E, et al. Lung Injury and Recovery in a Murine Model of Unilateral Acid Aspiration: Functional, Biochemical, and Morphologic Characterization. J Am Soc Anesthesiologists (2008) 108:1037–46. doi: 10.1097/ALN.0b013e318173f64f

74. Perug D-W, Chang K-T, Su K-C, Wu Y-C, Wu M-T, Hsu W-H, et al. Exposure of Airway Epithelium to Bile Acids Associated With Gastroesophageal Reflux Symptoms: A Relation to Transforming Growth Factor-β Production and Fibroblast Proliferation. Chest (2007) 132:1548–56. doi: 10.1378/chest.07-1371

75. Ménét D, Leblanc É, Lacasse Y. Meta-Analysis of Gastroesophageal Reflux Disease and Idiopathic Pulmonary Fibrosis. Chest (2015) 155:33–43. doi: 10.1016/j.chest.2014.07.038

76. Shao et al. Mechanisms and Managements of CTD-ILD
104. Sato T, Nakamura W, Inokuma S, Matsubara E. Characteristic Features of Talcum-Derived Lung Disease in Rheumatoid Arthritis Patients. *Clin Rheumatol* (2016) 35:541–5. doi: 10.1007/s10067-015-2865-6

105. Pechkovsky DV, Prasse A, Kollert F, Engel KM, Dentler J, Luttmann W, et al. Alternatively Activated Alveolar Macrophages in Pulmonary Fibrosis—Mediator Production and Intracellular Signal Transduction. *Clin Immunol* (2010) 137:89–101. doi: 10.1016/j.clim.2010.06.017

106. Liote H, Liote F, Séroussi B, Mayaud C, Cadranel J, Rituximab-Induced Lung Disease: A Systematic Literature Review. *Respir Med* (2009) 103:681–7. doi: 10.1016/j.rmed.2008.09.016

107. Curtis JR, Sarrouk I, Nakalov P, Costa LA, Schulman KL. Incidence and Complications of Interstitial Lung Disease in Users of Tocilizumab, Rituximab, Abatacept and Anti-Tumor Necrosis Factor Agents, a Retrospective Cohort Study. *Arthritis Res Ther* (2015) 17:319. doi: 10.1186/s13075-015-0835-7

108. Fragoulis GE, Conway R, Nikiphorou E. Methotrexate and Intersitial Lung Disease: Controversies and Questions. A Narrative Review of the Literature. *Rheumatol (Oxford)* (2019) 58:1900–6. doi: 10.1093/rheumatology/kez337

109. Ibfelt EH, Jacobsen RK, Kopp TI, Cordtz RL, Jakobsen AS, Seersholm N, et al. Methotrexate and Risk of Interstitial Lung Disease and Respiratory Failure in Rheumatoid Arthritis: A Nationwide Population-Based Study. *Rheumatol (Oxford)* (2021) 60:364–52. doi: 10.1093/rheumatology/keaa327

110. Dawson J, Graham D, Desmond J, Jewis A, Lynch M. Investigation of the Chronic Pulmonary Effects of Low-Dose Oral Methotrexate in Patients With Rheumatoid Arthritis: A Prospective Study Incorporating HRCT Scanning and Pulmonary Function Tests. *Rheumatology* (2002) 41:262–7. doi: 10.1093/rheumatology/41.3.262

111. Niell P, Busby AD, Nikiphorou E, Sullivan K, Walsh DA, Creamer P, et al. Is Incident Rheumatoid Arthritis Interstitial Lung Disease Associated With Methotrexate Treatment? Results From a Multivariate Analysis in the ERAS and ERAN Inception Cohorts. *BMJ Open* (2019) 9:e028466. doi: 10.1136/bmjopen-2018-028466

112. Deane KD, Nicolls MR. Developing Better Biomarkers for Connective Tissue Disease-Associated Interstitial Lung Disease: Citrullinated hsp90 Autoantibodies in Rheumatoid Arthritis. *Arthritis Rheum* (2011) 65:864–8. doi: 10.1002/art.37878

113. Turesson C, Matteson EL, Colby TV, Vuk-Pavlovic Z, Vassallo R, Weyand CM, et al. Increased Cd4+ T Cell Infiltrates in Rheumatoid Arthritis-Associated Interstitial Pneumonitis Compared With Idiopathic Interstitial Pneumonitis. *Arthritis Rheum* (2005) 52:73–9. doi: 10.1002/art.20765

114. Atkins SR, Turesson C, Myers JL, Tazelaar HD, Ryu JH, Matteson EL, et al. Morphologic and Quantitative Assessment of CD20+ B Cell Infiltrates in Rheumatoid Arthritis-Associated Non-specific Interstitial Pneumonia and Usual Interstitial Pneumonia. *Arthritis Rheum* (2006) 54:635–41. doi: 10.1002/art.21758

115. Wollin L, Ostermann A, Williams C. Nintedanib Inhibits Pro-Fibrotic Mediators From T Cells With Relevance to Connective Tissue Disease-Associated Interstitial Lung Disease. *Inh Eur Respir Soc* (2017) 50:PA903. doi: 10.1183/13993003.congress-2017.PA903

116. Shao et al. Mechanisms and Management of CTD-ILD
Idiopathic Pulmonary Fibrosis. Eur Respir J (2002) 19:439–46. doi: 10.1183/09031936.02.00081102

207. Bonhoff O, Andrei B, Gester F, de Seny D, Moermans C, Strumman I, et al. Biomarkers in Systemic Sclerosis-Associated Interstitial Lung Disease: Review of the Literature. Rheumatol (Oxford) (2019) 58:1534–46. doi: 10.1093/rheumatology/kez230

208. Kolb M, Bondue B, Pesci A, Miyazaki Y, Song JW, Bhattacharyya S, et al. Acute Exacerbations of Progressive-Fibrosing Interstitial Lung Diseases. Eur Respir J (2018) 52:180071. doi: 10.1183/16000617.0071-2018

209. Chartrand S, Fischer A. Management of Connective Tissue Disease-Associated Interstitial Lung Disease. Rheumatic Dis Clinics (2015) 41:279–94. doi: 10.1016/j.rdc.2015.01.002

210. Lee AS, Corte TJ. Current and Emerging Drug Therapies for Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): Drugs (2019) 79:1511–28. doi: 10.3862/0925-0197-1178-x

211. Zszeni F, Fukuoka J. Pathology of Idiopathic Interstitial Pneumonias. Surg Pathol Clinics (2020) 13:91–118. doi: 10.1016/j.pathv.2019.11.006

212. Distler O, Highland KH, Gahleimman A, Aiser F, Aysel MD, et al. Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease. N Engl J Med (2019) 380:2518–28. doi: 10.1056/NEJMoa1903076

213. Li T, Guo L, Chen Z, Wu L, Sun F, Tan X, et al. Pirfenidone in Patients With Rapidly Progressive Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis. Sci Rep (2016) 6:33226. doi: 10.1038/srep33226

214. Maher TM, Corte TJ, Fischer A, Kreuter M, Lederer DJ, Molina-Molina M, de Carvalho CRR, Deheinzelin D, Kairalla RA, King TE Jr, Hollingsworth H. Tashkin DP, Roth MD, Clements PJ, Furst DE, Khanna D, Kleerup EC, et al. Treatment and Prognosis of Interstitial Lung Disease in Systemic Sclerosis. Eur Respir J (2018) 52:180071. doi: 10.1183/16000617.0071-2018

215. Labirua-Iturburu A, Selva-O´s E, Labrador-Horrillo M, Vilardell-Tarrés M. Calcineurin Inhibitors in a Cohort of Patients With Antisynthetase-Associated Interstitial Lung Disease. Clin Exp Rheumatol (2013) 31:436–9. doi: 10.1016/j.jspri.2012.09.027

216. Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, et al. Impact of Adding Tacrolimus to Initial Treatment of Interstitial Pneumonitis in Polymyositis/ Dermatomyositis: A Single-Arm Clinical Trial. Rheumatol (Oxford) (2020) 59:1084–93. doi: 10.1093/rheumatology/kez394

217. Tsuji H, Nakashima R, Hosono Y, Imaura Y, Yagita M, Yoshufuji H, et al. Multicenter Prospective Study of the Efficacy and Safety of Combined Immunosuppressive Therapy With High-Dose Glucocorticoid, Tacrolimus, and Cyclophosphamide in Interstitial Lung Diseases Accompanied by Anti-Melanoma Differentiation-Associated Gene 5-Positive Dermatomyositis. Arthritis Rheumatol (2020) 72:488–98. doi: 10.1002/art.41105

218. Keir GJ, Maher TM, Ding D, Abdullah R, de Lauretis A, Wickremainge M, et al. Rituximab in Severe, Treatment-Refractory Interstitial Lung Disease. Respir (2014) 19:353–9. doi: 10.1111/respi.12214

219.Sharp C, McCabe M, Dowds N, Eday A, Mayers L, Adamali H, et al. Rituximab in Autoimmune Connective Tissue Disease-Associated Interstitial Lung Disease. Rheumatol (Oxford) (2016) 55:1318–24. doi: 10.1093/rheumatology/kew195

220. Yang L, Wang Q, Hou Y, Zhao J, Li M, Xu D, et al. The Chinese Herb Tripterygium Wilfordii Hook F for the Treatment of Systemic Sclerosis-Associated Interstitial Lung Disease: Data From a Chinese Eustar Center. Clin Rheumatol (2020) 39:813–21. doi: 10.1007/s00296-019-04784-y

221. De Lauretis A, Sestini P, Pantelidis P, Hoyles R, Hansell DM, Goh NS, et al. Serum Interleukin 6 is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. J Rheumatol (2013) 40:435–46. doi: 10.3899/jrheum.120725

222. Khanna D, Lin CJF, Furst DE, Goldin J, Kim G, Kuwana M, et al. Tocilizumab in Systemic Sclerosis: A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial. Lancet Respir Med (2020) 8:963–74. doi: 10.1016/s2213-2600(19)30318-0

223. Khanna D, Denton CP, Jahreis A, van Laar JM, Frelch TM, Anderson ME, et al. Safety and Efficacy of Subcutaneous Tocilizumab in Adults With Systemic Sclerosis (faSScinate): A Phase 2, Randomised, Controlled Trial. Lancet (2016) 387:2630–40. doi: 10.1016/S0140-6736(16)30022-4

224. Khanna D, Denton CP, Lin CJ, van Laar JM, Frelch TM, Anderson ME, et al. Safety and Efficacy of Subcutaneous Tocilizumab in Systemic Sclerosis: Results From the Open-Label Period of a Phase II Randomised Controlled Trial (Fascionate). Ann Rheum Dis (2018) 77:212–20. doi: 10.1136/annrheumdis-2017-211682

225. Vicente-Rabaneda EF, Atienza-Mateo B, Blanco R, Cavagna L, Ancochea J, Cañcheda S, et al. Efficacy and Safety of Abatacept in Interstitial Lung Disease of Rheumatoid Arthritis: A Systematic Literature Review. Autoimmun Rev (2021) 20:102830. doi: 10.1016/j.autrev.2021.102830

226. Fernández-Díaz C, Cañcheda S, Melero-González RB, Ortiz-Sanzuán F, Juan-Mas A, Carrasco-Cubero C, et al. Abatacept in Interstitial Lung Disease Associated With Rheumatoid Arthritis: National Multicenter Study of 263 Patients. Rheumatol (Oxford) (2020) 59:3906–16. doi: 10.1136/rheumatology kea621

227. Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SL, Inoue Y, et al. Nintedanib in Progressive Fibrosing Interstitial Lung Diseases. New Engl J Med (2019) 381:1718–27. doi: 10.1056/NEJMoa1908681

228. Varga J, K. Tjr. Prognosis and Treatment of Interstitial Lung Disease in Systemic Sclerosis (faSScinate): A Phase 2, Randomised, Controlled Trial. Lancet Respir Med (2019) 1:456–65. doi: 10.1016/S2213-2600(19)30184-4

229. Oldham JM, Lee C, Valenz E, Witt LJ, Adegunsoye A, Hsu S, et al. Azathioprine Response in Patients With Fibrotic Connective Tissue Disease-Associated Interstitial Lung Disease. Respir Med (2016) 121:117–22. doi: 10.1016/j.rmed.2016.11.007
244. Erre GL, Sebastiani M, Manfredi A, Gerratana E, Atzeni F, Passiu G, et al. Anti-fibrotic Drugs in Connective Tissue Disease-Related Interstitial Lung Disease (CTD-ILD): From Mechanistic Insights to Therapeutic Applications. *Drugs Context* (2021) 10:2020-8-6. doi: 10.7573/dic.2020-8-6

245. Shirakashi M, Nakashima R, Tsuji H, Tanizawa K, Handa T, Hosono Y, et al. Efficacy of Plasma Exchange in anti-MDA5-positive Dermatomyositis With Interstitial Lung Disease Under Combined Immunosuppressive Treatment. *Rheumatol (Oxford)* (2020) 59:3284-92. doi: 10.1093/rheumatology/keaa123

246. van Bijnen S, de Vries-Bouwstra J, van den Ende CH, Boonstra M, Kroft L, Geurts B, et al. Predictive Factors for Treatment-Related Mortality and Major Adverse Events After Autologous Haematopoietic Stem Cell Transplantation for Systemic Sclerosis: Results of a Long-Term Follow-Up Multicentre Study. *Ann Rheum Dis* (2020) 79:1084-9. doi: 10.1136/annrheumdis-2020-217058

247. Kreuter M, Polke M, Walsh SLF, Krisam J, Collard HR, Chaudhuri N, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis: International Survey and Call for Harmonisation. *Eur Respir J* (2020) 55:1901760. doi: 10.1183/13993003.01760-2019

248. Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *Am J Respir Crit Care Med* (2016) 194:265-75. doi: 10.1164/rccm.201604-0801CI

249. Woolton SC, Kim DS, Kondoh Y, Chen E, Lee JS, Song JW, et al. Viral Infection in Acute Exacerbation of Idiopathic Pulmonary Fibrosis. *Am J Respir Crit Care Med* (2011) 183:1698-702. doi: 10.1164/rccm.201010-1752OC

250. Manfredi A, Sebastiani M, Cerri S, Vacchi C, Tonelli R, Della Casa G, et al. Acute Exacerbation of Interstitial Lung Diseases Secondary to Systemic Rheumatic Diseases: A Prospective Study and Review of the Literature. *J Thoracic Dis* (2019) 11:1621. doi: 10.21037/jtd.2019.03.28

251. Tachikawa R, Tomii K, Ueda H, Nagata K, Nanjo S, Sakurai A, et al. Clinical Features and Outcome of Acute Exacerbation of Interstitial Pneumonia: Collagen Vascular Diseases-Related Versus Idiopathic. *Respiration* (2012) 83:20-7. doi: 10.1159/000329893

252. Suda T, Kaida Y, Nakamura Y, Enomoto N, Fujisawa T, Imokawa S, et al. Acute Exacerbation of Interstitial Pneumonia Associated With Collagen Vascular Diseases. *Respir Med* (2009) 103:846–53. doi: 10.1016/j.rmed.2008.12.019

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
# Glossary

| Acronym | Term |
|---------|------|
| AECAs   | Anti-endothelial cell antibodies |
| anti-CCP | anti-cyclic citrullinated peptide |
| ARS     | anti-aminocyl-transfer RNA synthetase |
| ASS     | anti-synthetase syndrome |
| BALF    | bronchoalveolar lavage fluid |
| BECs    | bronchial epithelial cells |
| CCL18   | chemokine ligand 18 |
| COP     | cryptogenic organizing pneumonia |
| CTD     | Connective tissue disease |
| CyC     | cyclophosphamide |
| DAD     | diffuse alveolar damage |
| DILD    | drugs induced ILD |
| DIP     | desquamative interstitial pneumonia |
| DLCO    | diffusion capacity of the lung for carbon monoxide |
| DM      | dermatomyositis |
| DMARDs  | disease-modifying anti-rheumatic drugs |
| DPLDs   | diffuse parenchymal lung diseases |
| FVC     | forced vital capacity |
| GC      | glucocorticoid |
| GERD    | gastroesophageal reflux disease |
| GOOs    | ground-glass opacities |
| HDAC    | histone deacetylase |
| HRCT    | high resolution computed tomography |
| IIMs    | idiopathic inflammatory myopathies |
| IIP     | idiopathic interstitial pneumonia |
| ILD     | interstitial lung disease |
| IPAF    | interstitial pneumonia with autoimmune features |
| IPF     | idiopathic pulmonary fibrosis |
| KL-6    | Krebs von den Lungen-6 |
| LIP     | lymphoid interstitial pneumonia |
| LTL     | leukocyte telomere length |
| MAAs    | myositis-associated antibodies |
| MCTD    | mixed connective tissue disease |
| MMPs    | matrix metalloproteinases |
| MSAs    | myositis-specific autoantibodies |
| MTX     | methotrexate |
| NSIP    | nonspecific interstitial pneumonia |
| OP      | organizing pneumonia |
| PF-ILD  | progressive fibrosing-ILD |
| PM      | polymyositis |
| RA      | rheumatoid arthritis |
| RB      | respiratory bronchiolitis |
| RNP     | ribonucleoprotein |
| RV      | residual volume |
| SAFB    | scaffold attachment factor B |
| SLE     | systemic lupus erythematosus |
| SP-D    | surfactant protein-D |
| SS      | Sjogren’s syndrome |
| SSc     | systemic sclerosis |
| TGF-β    | transforming growth factor-β |
| TLC     | total lung capacity |
| TLRs    | Toll-like receptors |
| TREM-1  | Triggering receptor expressed on myeloid cells 1 |
| UIP     | usual interstitial pneumonia |
| ZEB1    | zinc finger E-box-homeobox 1 |